|
1
|
Mehanna H, Paleri V, West CM and Nutting
C: Head and neck cancer - Part 1: Epidemiology, presentation, and
prevention. BMJ. 341:c46842010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wagenblast J, Hambek M, Baghi M, Gstöttner
W, Strebhardt K, Ackermann H and Knecht R: Antiproliferative
activity of bortezomib alone and in combination with cisplatin or
docetaxel in head and neck squamous cell carcinoma cell lines. J
Cancer Res Clin Oncol. 134:323–330. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Strebhardt K: Multifaceted polo-like
kinases: drug targets and antitargets for cancer therapy. Nat Rev
Drug Discov. 9:643–660. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Barr FA, Sillje HH and Nigg EA: Polo-like
kinases and the orchestration of cell division. Nat Rev Mol Cell
Biol. 5:429–440. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Andrysik Z, Bernstein WZ, Deng L, Myer DL,
Li YQ, Tischfield JA, et al: The novel mouse Polo-like kinase 5
responds to DNA damage and localizes in the nucleolus. Nucleic
Acids Res. 38:2931–2943. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Holtrich U, Wolf G, Bräuninger A, Karn T,
Böhme B, Rübsamen-Waigmann H and Strebhardt K: Induction and
down-regulation of PLK, a human serine/threonine kinase expressed
in proliferating cells and tumors. Proc Natl Acad Sci USA.
91:1736–1740. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lane HA and Nigg EA: Antibody
microinjection reveals an essential role for human polo-like kinase
1 (Plk1) in the functional maturation of mitotic centrosomes. J
Cell Biol. 135:1701–1713. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Spankuch B, Steinhauser I, Wartlick H,
Kurunci-Csacsko E, Strebhardt KI and Langer K: Downregulation of
Plk1 expression by receptor-mediated uptake of antisense
oligonucleotide-loaded nanoparticles. Neoplasia. 10:223–234.
2008.PubMed/NCBI
|
|
9
|
Van de Weerdt BC and Medema RH: Polo-like
kinases: a team in control of the division. Cell Cycle. 5:853–864.
2006.PubMed/NCBI
|
|
10
|
Steegmaier M, Hoffmann M, Baum A, Lénárt
P, Petronczki M, Krssák M, et al: BI 2536, a potent and selective
inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
Curr Biol. 17:316–322. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Takai N, Hamanaka R, Yoshimatsu J and
Miyakawa I: Polo-like kinases (Plks) and cancer. Oncogene.
24:287–291. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lénárt P, Petronczki M, Steegmaier M, Di
Fiore B, Lipp JJ, Hoffmann M, et al: The small-molecule inhibitor
BI 2536 reveals novel insights into mitotic roles of polo-like
kinase 1. Curr Biol. 17:304–315. 2007.PubMed/NCBI
|
|
13
|
Wagenblast J, Hirth D, Thron L, Arnoldner
C, Diensthuber M, Stöver T and Hambek M: Effects of the
Polo-like-kinase-1-inhibitor BI2536 in squamous cell carcinoma cell
lines of the head and neck. Oncol Lett. 4:175–177. 2012.PubMed/NCBI
|
|
14
|
Datta D, Banerjee P, Gasser M,
Waaga-Gasser AM and Pal S: CXCR3-B can mediate growth-inhibitory
signals in human renal cancer cells by down-regulating the
expression of heme oxygenase-1. J Biol Chem. 285:36842–36848. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ray RB, Raychoudhuri A, Steele R and
Nerurkar P: Bitter melon (Momordica charantia) extract
inhibits breast cancer cell proliferation by modulating cell cycle
regulatory genes and promotes apoptosis. Cancer Res. 70:1925–1931.
2010.PubMed/NCBI
|
|
16
|
Forastiere AA, Leong T, Rowinsky E, Murphy
BA, Vlock DR, DeConti RC and Adams GL: Phase III comparison of
high-dose paclitaxel + cisplatin + granulocyte colony-stimulating
factor versus low-dose paclitaxel + cisplatin in advanced head and
neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin
Oncol. 19:1088–1095. 2001.
|
|
17
|
Schrijvers D, Johnson J, Jiminez U, Gore
M, Kosmidis P, Szpirglas H, et al: Phase III trial of modulation of
cisplatin/ fluorouracil chemotherapy by interferon alfa-2b in
patients with recurrent or metastatic head and neck cancer. Head
and Neck Interferon Cooperative Study Group. J Clin Oncol.
16:1054–1059. 1998.PubMed/NCBI
|
|
18
|
Kohno N: The role of taxanes for head and
neck cancer. Gan To Kagaku Ryoho. 32:2035–2039. 2005.(In
Japanese).
|
|
19
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics. CA Cancer J Clin. 57:43–66.
2007.
|
|
20
|
Ackermann S, Goeser F, Schulte JH, Schramm
A, Ehemann V, Hero B, et al: Polo-like kinase 1 is a therapeutic
target in high-risk neuroblastoma. Clin Cancer Res. 17:731–741.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hu K, Lee C, Qiu D, Fotovati A, Davies A,
Abu-Ali S, et al: Small interfering RNA library screen of human
kinases and phosphatases identifies polo-like kinase 1 as a
promising new target for the treatment of pediatric
rhabdomyosarcomas. Mol Cancer Ther. 8:3024–3035. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chopra P, Sethi G, Dastidar SG and Ray A:
Polo-like kinase inhibitors: an emerging opportunity for cancer
therapeutics. Expert Opin Investig Drugs. 19:27–43. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Knecht R, Oberhauser C and Strebhardt K:
PLK (polo-like kinase), a new prognostic marker for oropharyngeal
carcinomas. Int J Cancer. 89:535–536. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Knecht R, Elez R, Oechler M, Solbach C,
von Ilberg C and Strebhardt K: Prognostic significance of polo-like
kinase (PLK) expression in squamous cell carcinomas of the head and
neck. Cancer Res. 59:2794–2797. 1999.PubMed/NCBI
|
|
25
|
Mross K, Frost A, Steinbild S, Hedbom S,
Rentschler J, Kaiser R, et al: Phase I dose escalation and
pharmacokinetic study of BI 2536, a novel Polo-like kinase 1
inhibitor, in patients with advanced solid tumors. J Clin Oncol.
26:5511–5517. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schöffski P, Blay JY, De Greve J, Brain E,
Machiels JP, Soria JC, et al: Multicentric parallel phase II trial
of the polo-like kinase 1 inhibitor BI 2536 in patients with
advanced head and neck cancer, breast cancer, ovarian cancer, soft
tissue sarcoma and melanoma. The first protocol of the European
Organization for Research and Treatment of Cancer (EORTC) Network
Of Core Institutes (NOCI). Eur J Cancer. 46:2206–2215. 2010.
|
